Assessing liquid biopsy for mature B-cell tumors
Prospective, Observational, Multi-centred, Non-interventional Research Project on Plasma Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Tumor Management
This study tests if analyzing DNA from blood samples can help predict treatment outcomes for patients with mature B-cell tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 444 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oncology Institute of Southern Switzerland Academic / other |
| Locations | 1 site (Bellinzona, Canton Ticino) |
| Trial ID | NCT03280394 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of cell-free DNA genotyping in predicting treatment outcomes for patients with mature B-cell tumors. It involves collecting clinical data and blood samples at various stages of diagnosis and treatment to analyze the relationship between genetic biomarkers and patient prognosis. The study aims to improve the accuracy of early predictions of cure and identify drug-resistance mutations during treatment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a documented diagnosis of mature B-cell tumors.
Not a fit: Patients without a diagnosis of mature B-cell tumors or those unable to comply with study procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate predictions of treatment outcomes and personalized treatment strategies for patients with mature B-cell tumors.
How similar studies have performed: Other studies have shown promise in using liquid biopsy approaches for cancer diagnostics, indicating potential success for this methodology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female adults 18 years or older * Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria * Willing and able to comply with scheduled study procedures * Evidence of a signed informed consent
Where this trial is running
Bellinzona, Canton Ticino
- Institute of Oncology Research — Bellinzona, Canton Ticino, Switzerland (Recruiting)
Study contacts
- Principal investigator: Davide Rossi, MD, PhD — Oncology Institute of Southern Switzerland
- Study coordinator: Davide Rossi, MD, PhD
- Email: davide.rossi@eoc.ch
- Phone: +41 091 811 8540
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.